BETHKIS® (Tobramycin Inhalation Solution)

Concentrated Formulation for Efficient Nebulization

Concentrated Formulation for Efficient Nebulization

300 mg of Tobramycin in Only 4 mL1,2

BETHKIS® (Tobramycin Inhalation Solution) is a concentrated solution delivering 300 mg of nebulized tobramycin in only 4 mL.1 The solution offers osmolarity similar to that of airway surface liquid in patients with cystic fibrosis.3,4

Efficient Nebulization
  • Approximate 15-minute administration time1
Benefits Demonstrated in Pivotal Clinical Studies vs Placebo
  • Proven efficacy
    • Significant improvements in lung function, decrease in density of Pseudomonas aeruginosa in sputum, and reduced patient burden1,3-5
  • Favorable safety profile
    • Adverse event rates similar to placebo1
    • Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation rate increased, and dysphonia
  • Local tolerability
    • Generally well tolerated with a low incidence of voice alteration and bronchospasm1,6
    • Incidence of wheezing similar to placebo1,6
  • High compliance
    • Mean treatment compliance ≥98% across clinical trials3,6

BETHKIS® (Tobramycin Inhalation Solution) is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.

Important Safety Information

BETHKIS is contraindicated in patients with a known hypersensitivity to any aminoglycoside.

Bronchospasm can occur with inhalation of BETHKIS. Bronchospasm and wheezing should be treated as medically appropriate.

Caution should be exercised when prescribing BETHKIS to patients with known or suspected auditory, vestibular, renal, or neuromuscular dysfunction. Audiograms, serum concentration, and renal function should be monitored as appropriate.

Avoid concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic or ototoxic potential.

BETHKIS should not be administered concurrently with ethacrynic acid, furosemide, urea, or mannitol.

Aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function.

Fetal harm can occur when aminoglycosides are administered to a pregnant woman. Apprise women of the potential hazard to the fetus.

Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation rate increased, and dysphonia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


Please see full prescribing information.


This website is intended for United States residents only.

References: 1. BETHKIS [package insert]. Cary, NC: Chiesi USA, Inc.; 2014. 2. TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009. 3. Chuchalin A, Csiszér E, Gyurkovics K, et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr Drugs. 2007;9(suppl 1):21-31. 4. Poli G, Acerbi D, Pennini R, et al. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi®. Pediatr Drugs. 2007;9(suppl 1):3-9. 5. Data on file. Chiesi USA, Inc. 6. Lenoir G, Antypkin YG, Miano A, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Drugs. 2007;9(suppl 1):11-20.

Get the latest information about BETHKIS® (Tobramyin Inhalation Solution) as it becomes available.

First Name*

Last Name*


By submitting your e-mail address, you are giving Chiesi USA, Inc. permission to send you information and updates on BETHKIS or other treatment-related information in the future. Chiesi USA, Inc. will not sell or share any of your information with third parties.